Patient derived organoids to model rare prostate cancer phenotypes

There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify ther...

Full description

Bibliographic Details
Main Authors:	Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R. Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta, Verena Sailer, Aram Vosoughi, Chantal Pauli, Yelena Churakova, Cynthia Cheung, Lesa Dayal Deonarine, Terra J. McNary, Rachele Rosati, Scott T. Tagawa, David M. Nanus, Juan Miguel Mosquera, Charles L. Sawyers, Yu Chen, Giorgio Inghirami, Rema A. Rao, Carla Grandori, Olivier Elemento, Andrea Sboner, Francesca Demichelis, Mark A. Rubin, Himisha Beltran
Format:	Article
Language:	English
Published:	Nature Publishing Group 2018-06-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-018-04495-z

id	doaj-6298c3191ca44642a1ee5adc286008a4
record_format	Article
spelling	doaj-6298c3191ca44642a1ee5adc286008a42021-05-11T09:52:05ZengNature Publishing GroupNature Communications2041-17232018-06-019111010.1038/s41467-018-04495-zPatient derived organoids to model rare prostate cancer phenotypesLoredana Puca0Rohan Bareja1Davide Prandi2Reid Shaw3Matteo Benelli4Wouter R. Karthaus5Judy Hess6Michael Sigouros7Adam Donoghue8Myriam Kossai9Dong Gao10Joanna Cyrta11Verena Sailer12Aram Vosoughi13Chantal Pauli14Yelena Churakova15Cynthia Cheung16Lesa Dayal Deonarine17Terra J. McNary18Rachele Rosati19Scott T. Tagawa20David M. Nanus21Juan Miguel Mosquera22Charles L. Sawyers23Yu Chen24Giorgio Inghirami25Rema A. Rao26Carla Grandori27Olivier Elemento28Andrea Sboner29Francesca Demichelis30Mark A. Rubin31Himisha Beltran32Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalCenter for Integrative Biology, University of TrentoCure First and SEngine Precision MedicineCenter for Integrative Biology, University of TrentoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalMeyer Cancer Center, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalCure First and SEngine Precision MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineMeyer Cancer Center, Weill Cornell MedicineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalCure First and SEngine Precision MedicineMeyer Cancer Center, Weill Cornell MedicineEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian HospitalDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineThere are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations.https://doi.org/10.1038/s41467-018-04495-z
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Loredana Puca Rohan Bareja Davide Prandi Reid Shaw Matteo Benelli Wouter R. Karthaus Judy Hess Michael Sigouros Adam Donoghue Myriam Kossai Dong Gao Joanna Cyrta Verena Sailer Aram Vosoughi Chantal Pauli Yelena Churakova Cynthia Cheung Lesa Dayal Deonarine Terra J. McNary Rachele Rosati Scott T. Tagawa David M. Nanus Juan Miguel Mosquera Charles L. Sawyers Yu Chen Giorgio Inghirami Rema A. Rao Carla Grandori Olivier Elemento Andrea Sboner Francesca Demichelis Mark A. Rubin Himisha Beltran
spellingShingle	Loredana Puca Rohan Bareja Davide Prandi Reid Shaw Matteo Benelli Wouter R. Karthaus Judy Hess Michael Sigouros Adam Donoghue Myriam Kossai Dong Gao Joanna Cyrta Verena Sailer Aram Vosoughi Chantal Pauli Yelena Churakova Cynthia Cheung Lesa Dayal Deonarine Terra J. McNary Rachele Rosati Scott T. Tagawa David M. Nanus Juan Miguel Mosquera Charles L. Sawyers Yu Chen Giorgio Inghirami Rema A. Rao Carla Grandori Olivier Elemento Andrea Sboner Francesca Demichelis Mark A. Rubin Himisha Beltran Patient derived organoids to model rare prostate cancer phenotypes Nature Communications
author_facet	Loredana Puca Rohan Bareja Davide Prandi Reid Shaw Matteo Benelli Wouter R. Karthaus Judy Hess Michael Sigouros Adam Donoghue Myriam Kossai Dong Gao Joanna Cyrta Verena Sailer Aram Vosoughi Chantal Pauli Yelena Churakova Cynthia Cheung Lesa Dayal Deonarine Terra J. McNary Rachele Rosati Scott T. Tagawa David M. Nanus Juan Miguel Mosquera Charles L. Sawyers Yu Chen Giorgio Inghirami Rema A. Rao Carla Grandori Olivier Elemento Andrea Sboner Francesca Demichelis Mark A. Rubin Himisha Beltran
author_sort	Loredana Puca
title	Patient derived organoids to model rare prostate cancer phenotypes
title_short	Patient derived organoids to model rare prostate cancer phenotypes
title_full	Patient derived organoids to model rare prostate cancer phenotypes
title_fullStr	Patient derived organoids to model rare prostate cancer phenotypes
title_full_unstemmed	Patient derived organoids to model rare prostate cancer phenotypes
title_sort	patient derived organoids to model rare prostate cancer phenotypes
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2018-06-01
description	There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations.
url	https://doi.org/10.1038/s41467-018-04495-z
work_keys_str_mv	AT loredanapuca patientderivedorganoidstomodelrareprostatecancerphenotypes AT rohanbareja patientderivedorganoidstomodelrareprostatecancerphenotypes AT davideprandi patientderivedorganoidstomodelrareprostatecancerphenotypes AT reidshaw patientderivedorganoidstomodelrareprostatecancerphenotypes AT matteobenelli patientderivedorganoidstomodelrareprostatecancerphenotypes AT wouterrkarthaus patientderivedorganoidstomodelrareprostatecancerphenotypes AT judyhess patientderivedorganoidstomodelrareprostatecancerphenotypes AT michaelsigouros patientderivedorganoidstomodelrareprostatecancerphenotypes AT adamdonoghue patientderivedorganoidstomodelrareprostatecancerphenotypes AT myriamkossai patientderivedorganoidstomodelrareprostatecancerphenotypes AT donggao patientderivedorganoidstomodelrareprostatecancerphenotypes AT joannacyrta patientderivedorganoidstomodelrareprostatecancerphenotypes AT verenasailer patientderivedorganoidstomodelrareprostatecancerphenotypes AT aramvosoughi patientderivedorganoidstomodelrareprostatecancerphenotypes AT chantalpauli patientderivedorganoidstomodelrareprostatecancerphenotypes AT yelenachurakova patientderivedorganoidstomodelrareprostatecancerphenotypes AT cynthiacheung patientderivedorganoidstomodelrareprostatecancerphenotypes AT lesadayaldeonarine patientderivedorganoidstomodelrareprostatecancerphenotypes AT terrajmcnary patientderivedorganoidstomodelrareprostatecancerphenotypes AT rachelerosati patientderivedorganoidstomodelrareprostatecancerphenotypes AT scottttagawa patientderivedorganoidstomodelrareprostatecancerphenotypes AT davidmnanus patientderivedorganoidstomodelrareprostatecancerphenotypes AT juanmiguelmosquera patientderivedorganoidstomodelrareprostatecancerphenotypes AT charleslsawyers patientderivedorganoidstomodelrareprostatecancerphenotypes AT yuchen patientderivedorganoidstomodelrareprostatecancerphenotypes AT giorgioinghirami patientderivedorganoidstomodelrareprostatecancerphenotypes AT remaarao patientderivedorganoidstomodelrareprostatecancerphenotypes AT carlagrandori patientderivedorganoidstomodelrareprostatecancerphenotypes AT olivierelemento patientderivedorganoidstomodelrareprostatecancerphenotypes AT andreasboner patientderivedorganoidstomodelrareprostatecancerphenotypes AT francescademichelis patientderivedorganoidstomodelrareprostatecancerphenotypes AT markarubin patientderivedorganoidstomodelrareprostatecancerphenotypes AT himishabeltran patientderivedorganoidstomodelrareprostatecancerphenotypes
_version_	1721449055614140416

Patient derived organoids to model rare prostate cancer phenotypes

Similar Items